Lingtong Zhi, Xing Wang, Qing Gao, Wenhui He, Chongye Shang, Changjiang Guo a, Zhiyuan Niu, Wuling Zhu*, Xuan Zhang*. Intrinsic and extrinsic factors determining natural killer cell fate: Phenotype and function.Biomedicine & Pharmacotherapy,2023, 165:115136. [DOI][PubMed][Elsevier]
Changjiang Guo#*, Han Chen#, Jie Yu, Hui Lu, Qing Xia, Xiaojuan Li, Xiali Guo, Tong Wang, Lingtong Zhi, Zhiyuan Niu, Wuling Zhu*. Engagement of an optimized lentiviral vector enhances the expression and cytotoxicity of CAR in human NK cells. Molecular Immunology, 2023, 155:91-99. [DOI][PubMed][Elsevier]
Zhiyuan Niu#*,Zhixia Luo, Pengyang Sun, Linwei Ning, Xinru Jin, Guanxu Chen, Changjiang Guo, Lingtong Zhi, Wei Chang, Wuling Zhu*. In vitro nanobody library construction by using gene designated-region pan-editing technology. BioDesign Research, 2022, 2022:9823578. [DOI]
Lingtong Zhi#, Meichen Yin#, Xin Su, Zikang Zhang, Hui Lu, Mingfeng Li, Changjiang Guo, Zhiyuan Niu, Xuan Zhang, Wuling Zhu*. A chimeric switch-receptor PD1-DAP10-41BB augments NK92-cell activation and killing for human lung Cancer H1299 Cell. Biochemical and Biophysical Research Communications, 2022, 600(3):94-100. [DOI][PubMed][Elsevier]
Lingtong Zhi#, Xin Su, Meichen Yin, Zikang Zhang, Hui Lu, Zhiyuan Niu, Changjiang Guo, Wuling Zhu*, Xuan Zhang*. Genetical engineering for NK and T cell immunotherapy with CRISPR/Cas9 technology: Implications and challenges. Cellular Immunology, 2021, 369:104436. [DOI][PubMed][Elsevier]
Huiyong Zhang#, Enchao Jia#, Wenjiao Xia, Chengui Lu, Wuling Zhu*. VEGF165b mutant with a prolonged half-life and enhanced anti-tumor potency in a mouse model. Journal of Biotechnology, 2018, 284:84–90. [DOI][PubMed][Elsevier]
